Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
Previous reports have shown that interferon (IFN)-based therapy decreases the risk of development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection. However, it remains to be fully elucidated whether elimination of HCV by IFN-based therapy inhibits HCC recurrence after curative treatment, such as surgical resection and local ablation therapies. In this study, we aimed to clarify the influence of a sustained virological response (SVR) after IFN-based therapy on recurrence and survival after curative treatment of HCC. Fifty-one patients who underwent curative treatment of HCV-related HCC after receiving IFN-based therapy were analyzed retrospectively. They were classified into SVR (N = 14) and non-SVR groups (N = 37). In the SVR group, serum levels of aspartate aminotransferase and alanine aminotransferase, the indocyanine green retention rate at 15 min, and the percentages of patients with liver cirrhosis and HCV serotype 1 were significantly lower, whereas serum albumin level and platelet count were significantly higher upon HCC occurrence. Recurrence-free survival (RFS) for the first recurrence was significantly higher in the SVR group (P < 0.01). Multivariate analysis showed that SVR at initial HCC treatment (P < 0.01) and multiple tumors (P < 0.01) are prognostic factors for RFS. Moreover, RFS for the second recurrence showed a similar trend to that for the first recurrence. In conclusion, patients who underwent IFN-based therapy before initial curative treatment of HCC had a favorable clinical outcome compared with non-SVR patients.
1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan;
Tomoko
T
Saito
1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan;
Tetsuhiro
T
Chiba
1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan;
Eiichiro
E
Suzuki
2. Department of Medicine, Numazu City Hospital, Numazu, Shizuoka, Japan;
Masami
M
Shinozaki
2. Department of Medicine, Numazu City Hospital, Numazu, Shizuoka, Japan;
Nobuaki
N
Goto
1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan;
Naoya
N
Kanogawa
1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan;
Tenyu
T
Motoyama
1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan;
Sadahisa
S
Ogasawara
1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan;
Yoshihiko
Y
Ooka
1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan;
Akinobu
A
Tawada
1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan;
Tatsuo
T
Kanda
3. Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Masaru
M
Miyazaki
1. Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan;
Osamu
O
Yokosuka
D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D018572:Disease-Free Survival; D005260:Female; D016174:Hepacivirus / Q000187:drug effects; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology
D007372:Interferons
HCC; HCV; IFN; SVR.; recurrence